Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 12/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.63 |
| ▸ | GAA | P10253 | 8/20 | 0.63 |
| ▸ | MEN1 | O00255 | 7/20 | 0.63 |
| ▸ | LMNA | P02545 | 6/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
| ▸ | PIKFYVE | Q9Y2I7 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.60 |
| ▸ | THRB | P10828 | 2/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | RECQL | P46063 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 3/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL427196 | 0.90 | MAPT (0.62) | MAPTKMT2AGAAMEN1LMNA | |
| SCHEMBL10196380 | 0.90 | MAPT (0.62) | MAPTKMT2AGAAMEN1LMNA | |
| SCHEMBL427195 | 0.90 | MAPT (0.62) | MAPTKMT2AGAAMEN1LMNA | |
| SCHEMBL422581 | 0.86 | MAPT (0.49) | MAPTKMT2AGAAMEN1LMNA | |
| SCHEMBL10195935 | 0.86 | MAPT (0.49) | MAPTKMT2AGAAMEN1LMNA | |
| SCHEMBL422582 | 0.86 | MAPT (0.49) | MAPTKMT2AGAAMEN1LMNA | |
| SCHEMBL426270 | 0.85 | MAPT (0.68) | MAPTKMT2AGAAMEN1LMNA | |
| SCHEMBL426269 | 0.85 | MAPT (0.68) | MAPTKMT2AGAAMEN1LMNA | |
| SCHEMBL10196633 | 0.85 | MAPT (0.68) | MAPTKMT2AGAAMEN1LMNA | |
| SCHEMBL3325959 | 0.85 | MAPT (0.62) | MAPTKMT2AGAAMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150174132-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP (US) | 2015-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150174132-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | REL, NFATC1, BCL6 | MAPT 4316/4885KMT2A 1509/4885GAA 3596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.